CCM
CLRB icon

Consonance Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Consonance Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,043
Closed -$4.66M – 20
2021
Q2 		$4.66M Sell
13,043
-537
-4% -$233K 0.56% 21
2021
Q1 		$6.56M Hold
13,580
– – 0.7% 26
2020
Q4 		$8.47M Buy
+13,580
New +$6.24M 0.79% 27

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Consonance Capital Management's CLRB Position: Q3 2021 in Review

Consonance Capital Management sold out of Cellectar Biosciences (CLRB) in Q3 2021, closing a stake of 13,043 shares — an estimated $4.66M sold.

Consonance Capital Management first reported a position in CLRB in Q4 2020 and held it in 3 quarters. The position peaked at $8.47M in Q4 2020. 38 funds tracked by Wall St. Rank hold CLRB as of Q3 2021.

  • Consonance Capital Management reported no remaining Cellectar Biosciences position as of Q3 2021 after selling out during the quarter.
  • Consonance Capital Management sold 13,043 Cellectar Biosciences shares in Q3 2021, an estimated $4.66M.
  • Consonance Capital Management first reported a position in Cellectar Biosciences in Q4 2020 and held it in 3 quarters.
  • Consonance Capital Management's Cellectar Biosciences position peaked at $8.47M in Q4 2020.
  • 38 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2021.

Based on Consonance Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.